CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
India’s HealthKart valued at $500M in new investment

From TechCrunch

By Manish Singh

November 18, 2024

India’s HealthKart valued at $500M in new investment

India’s HealthKart valued at $500M in new investment

Indian nutrition startup HealthKart’s valuation has surged to about $500 million in a new all-secondary investment of $153 million, two sources familiar with the matter told TechCrunch.

The investment, one of the largest for an Indian consumer startup this year, was co-led by private equity firms ChrysCapital and Motilal Oswal, with Avendus Capital serving as financial advisor. A91 Partners and asset manager Neo Group also participated in the round. The startup was previously valued at $350 million.

Some of the startup’s older investors sold their shares to the new backers, the sources said. Peak XV, formerly known as Sequoia India and Southeast Asia, has fully exited the startup, selling shares it bought for less than $30 million for about $120 million. HealthKart also counts Temasek, Sofina and wealth manager IIFL among its backers.

Gurugram-based HealthKart reported revenue of $118.5 million for the year ended March 2024, cementing its position as India’s largest consumer nutrition platform. The startup sells protein supplements and health accessories.

The 13-year-old startup, which spun out of online pharmacy startup 1MG, said on Thursday that it is buying back shares worth $6.5 milion from employees. The startup was EBITDA profitable in the financial year ended March.

“The Indian sports nutrition market, currently underpenetrated, is expected to expand due to a rise in fitness awareness and the increasing importance of nutrition and protein,” said Arpit Vinayak, VP at ChrysCapital, in a statement.

View original article on techcrunch.com

Most Recent

Amazon is taking its biggest shot at Nvidia yet with new TorchNeuron dev tool

Amazon wants to break Nvidia’s hold on PyTorch, the free toolkit used to build most AI apps, so that more developers run their apps on alternative chips like its own.

Oct 19, 2026

Replika’s founder built the AI assistant she pitched at Disrupt 12 years ago

Eugenia Kuyda's newest startup Wabi is positioned to take advantage of an idea she had more than a decade ago. Wabi offers a personal AI assistant with a twist, free and downloadable to anyone today.

Oct 19, 2026

AI assistant startup Town nabs unicorn valuation 4 months after launch

AI assistant startup Town nabbed a unicorn valuation on Monday, announcing a $108 million Series B round co-led by Forerunner Ventures and Menlo Ventures.

Oct 19, 2026

Khosla Ventures doubles down on Even Healthcare to challenge India’s hospital economics

Even Healthcare reaches a $300 million valuation in a Khosla Ventures-led round as it plans to expand its hospital network in India.

Oct 19, 2026

Similar Posts

ChrysCapital invests $100 million in India’s Lenskart

ChrysCapital has invested $100 million in Lenskart, the two said Thursday, pushing the Asian eyewear startup’s raise in the past year to $850 million as it expands its offerings and reach in international markets. The Indian venture firm is buying shares worth $100 million in Lenskart through both primary and secondary transactions, the two said. […]

Jun 14, 2023

Zepto eyes $100M from Indian offices in third funding in 6 months

Zepto is in advanced stages of talks to raise $100 million in new investment, its third in the last six months, as the leading Indian quick commerce startup looks to rope in more domestic investors, sources familiar with the talks told TechCrunch. The Mumbai-headquartered startup, which delivers grocery items and office stationery to customers’ doorsteps in 10 minutes in multiple Indian cities, is raising the new investment from Indian family offices and high net worth individuals. Motilal Oswa

Oct 17, 2024

ADIA invests $500 million in Lenskart

Lenskart has signed a definitive agreement to raise $500 million from the Abu Dhabi Investment Authority, they said Wednesday, at the height of the market slump as the Indian eyewear retailer bulks up its offerings and scales to international markets. The investment, an extension to last year’s round, helps the startup retain its $4.5 billion […]

Mar 15, 2023

PharmEasy’s $5.6 billion value shrinks to $456 million, investor data shows

Indian online pharmacy PharmEasy’s valuation now stands at about $456 million, according to disclosures from its investor Janus Henderson, a 92% drop from its peak valuation of $5.6 billion. The British American global asset firm’s Global Research Fund values its holding of 12.9 million shares in PharmEasy at $766,043, according to its latest filing for the period ending September. The fund had originally spent $9.4 million to acquire these shares. The persistent low valuation comes despite Pha

Dec 25, 2024